halaven
Selected indexed studies
- Eribulin. (, 2006) [PMID:36780412]
- Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer. (Breast Cancer (Dove Med Press), 2011) [PMID:24367180]
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (Lancet, 2016) [PMID:26874885]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (2016) pubmed
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. (2011) pubmed
- Eribulin. (2011) pubmed
- Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. (2015) pubmed
- Eribulin. (2006) pubmed
- Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer. (2011) pubmed
- [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer]. (2011) pubmed
- Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with Fluphenazine. (2016) pubmed
- [Clinical benefit of eribulin (Halaven(®)) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms]. (2016) pubmed
- Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug Distribution. (2025) pubmed